Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P13647: Variant p.Val186Met

Keratin, type II cytoskeletal 5
Gene: KRT5
Feedback?
Variant information Variant position: help 186 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help US The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Valine (V) to Methionine (M) at position 186 (V186M, p.Val186Met). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In EBS2B; uncertain significance. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 186 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 590 The length of the canonical sequence.
Location on the sequence: help TEEREQIKTLNNKFASFIDK V RFLEQQNKVLDTKWTLLQEQ The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 590 Keratin, type II cytoskeletal 5
Domain 168 – 481 IF rod
Region 168 – 203 Coil 1A



Literature citations
Epidermolysis bullosa simplex in Japanese and Korean patients: genetic studies in 19 cases.
Yasukawa K.; Sawamura D.; Goto M.; Nakamura H.; Jung S.-Y.; Kim S.-C.; Shimizu H.;
Br. J. Dermatol. 155:313-317(2006)
Cited for: VARIANTS EBS2C LEU-25; VAL-158 AND SER-352; VARIANTS EBS2B ASP-143; MET-186; LEU-186; PRO-191 AND ASP-517; VARIANTS EBS2A SER-176; LYS-475 AND LYS-477; VARIANT EBS2F LEU-25; Novel sporadic and recurrent mutations in KRT5 and KRT14 genes in Polish epidermolysis bullosa simplex patients: further insights into epidemiology and genotype-phenotype correlation.
Wertheim-Tysarowska K.; Oldak M.; Giza A.; Kutkowska-Kazmierczak A.; Sota J.; Przybylska D.; Wozniak K.; Sniegorska D.; Niepokoj K.; Sobczynska-Tomaszewska A.; Rygiel A.M.; Ploski R.; Bal J.; Kowalewski C.;
J. Appl. Genet. 57:175-181(2016)
Cited for: VARIANT EBS2F LEU-25; VARIANTS EBS2B ALA-143; LYS-170 AND MET-186; VARIANTS EPIDERMOLYSIS BULLOSA SIMPLEX PHE-143; LYS-190; MET-203; 470-TYR--SER-590 DEL AND GLY-477; VARIANT EBS2A 144-THR-VAL-145 DEL; VARIANTS EBS2C TYR-146; LYS-170; PHE-325; HIS-471 AND ASP-476;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.